CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 160 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $16 | -97.0% | 491 | -95.9% | 0.00% | -100.0% |
| Q4 2022 | $539 | -99.8% | 12,102 | +35.7% | 0.00% | – |
| Q3 2022 | $250,000 | -43.9% | 8,916 | -46.1% | 0.00% | – |
| Q2 2022 | $446,000 | +7.0% | 16,546 | +35.0% | 0.00% | – |
| Q1 2022 | $417,000 | -16.8% | 12,252 | -5.7% | 0.00% | -100.0% |
| Q4 2021 | $501,000 | -60.6% | 12,990 | -64.8% | 0.00% | 0.0% |
| Q3 2021 | $1,270,000 | +2.4% | 36,911 | -0.5% | 0.00% | 0.0% |
| Q2 2021 | $1,240,000 | +2284.6% | 37,111 | +1357.6% | 0.00% | – |
| Q1 2021 | $52,000 | -89.5% | 2,546 | -91.0% | 0.00% | -100.0% |
| Q4 2020 | $493,000 | +94.9% | 28,144 | +65.0% | 0.00% | – |
| Q3 2020 | $253,000 | -68.9% | 17,062 | -72.7% | 0.00% | -100.0% |
| Q2 2020 | $813,000 | +2610.0% | 62,592 | +356.7% | 0.00% | – |
| Q4 2019 | $30,000 | +275.0% | 13,705 | +227.6% | 0.00% | – |
| Q3 2019 | $8,000 | -46.7% | 4,183 | -27.4% | 0.00% | – |
| Q2 2019 | $15,000 | +275.0% | 5,765 | +596.3% | 0.00% | – |
| Q1 2019 | $4,000 | – | 828 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 1,605,390 | $71,552,232 | 10.98% |
| Octagon Capital Advisors LP | 761,398 | $33,935,509 | 5.28% |
| TSP Capital Management Group, LLC | 269,895 | $12,029,225 | 4.50% |
| Redmile Group, LLC | 1,977,451 | $88,134,991 | 3.60% |
| COMMODORE CAPITAL LP | 495,823 | $22,099 | 3.33% |
| Tri Locum Partners LP | 176,109 | $7,849,000 | 3.18% |
| ACUTA CAPITAL PARTNERS, LLC | 115,000 | $5,125,550 | 3.15% |
| Ikarian Capital, LLC | 267,476 | $11,921,406 | 2.88% |
| RTW INVESTMENTS, LP | 3,084,215 | $137,463,463 | 2.81% |
| Eversept Partners, LP | 558,774 | $24,904,557 | 2.18% |